Advertisement

Cardiologie pp 331-340 | Cite as

38 De implanteerbare cardioverter-defibrillator

  • M. J. Schalij
  • L. Van Erven
Part of the Quintessens book series (QUI)

Samenvatting

In Nederland worden jaarlijks 20.000-30.000 mensen getroffen door een acute circulatie- en ademstilstand. Bij 80% van hen wordt de circulatiestilstand veroorzaakt door een ventriculaire ritmestoornis (ventrikeltachycardie of -fibrilleren: VT/VF). Bij 50% is de aritmie het gevolg van acute ischemie en bij 50% wordt de ritmestoornis niet geluxeerd door ischemie. Momenteel wordt slechts 2-5% van deze patiënten met succes gereanimeerd en opgenomen in een ziekenhuis. De patiënten zonder acute ischemie hebben een kans op een recidief van de ritmestoornis van 20-40% per jaar.

Literatuur

  1. Bardy G, Lee K, Mark D, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Eng J Med. 2005;352:225–37.CrossRefGoogle Scholar
  2. Borger van der Burg AE, Bax JJ, Boersma E, et al. Impact of viability, ischemia, scar tissue, and revascularization on outcome after aborted sudden death. Circulation. 2003;108:1954–9.CrossRefGoogle Scholar
  3. Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Eng J Med. 2004;350:2140–50.CrossRefGoogle Scholar
  4. Buxton A, Lee K, Fisher J, et al. A randomized study of the prevention of sudden death in patients with coronary artery disease. N Eng J Med. 1999;341:1882–90.CrossRefGoogle Scholar
  5. Cleland JG, Daubert JC, Erdmann E, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Eng J Med. 2005;352:1539–49.CrossRefGoogle Scholar
  6. Gatzoulis MA, Till JA, Sommerville J, Redington AN. Mechanoelectrical interaction in tetralogy of Fallot. QRS prolongation relates to right ventricular size and predicts malignant ventricular arrhythmias and sudden death. Circulation. 1995;92:231–7.PubMedCrossRefGoogle Scholar
  7. Gould PA, Krahn AD, Canadian Heart Rhythm Society Working Group on Device Advisories. Complications associated with implantable cardioverter-defibrillator replacement in response to device advisories. JAMA. 2006;295:1907–11.Google Scholar
  8. Kadish A, Dyer A, Daubert J, et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Eng J Med. 2004;350:2151–8.CrossRefGoogle Scholar
  9. Kies P, Boersma E, Bax JJ, et al. Determinants of recurrent ventricular arrhythmia or death in 300 consecutive patients with ischemic heart disease who experienced aborted sudden death: data from the Leiden out-of-hospital cardiac arrest study. J Cardiovasc Electrophysiol. 2005;16:1049–56.PubMedCrossRefGoogle Scholar
  10. Kies P, Bootsma M, Bax J, et al. Arrhythmogenic right ventricular dysplasia/cardiomyopathy: screening, diagnosis, and treatment. Heart Rhythm. 2006;3:225–34.PubMedCrossRefGoogle Scholar
  11. Maron BJ, Shen WK, Link MS, et al. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N Eng J Med. 2000;342:365–73.CrossRefGoogle Scholar
  12. Mirowski M, Reid PR, Mower MM, et al. Termination of malignant ventricular arrhythmias with an implanted automatic defibrillator in human beings. N Eng J Med. 1980;303:322–4.CrossRefGoogle Scholar
  13. Moss A, Hall J, Cannom D, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk of ventricular arrhythmias. N Eng J Med. 1996;335:1933–40.CrossRefGoogle Scholar
  14. Moss A, Zareba W, Hall WJ, Klein H, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Eng J Med. 2002;346:877–83.CrossRefGoogle Scholar
  15. Rooden CJ van, Molhoek SG, Rosendaal FR. Incidence and risk factors of early venous thrombosis associated with permanent pacemaker leads. J Cardiovasc Electrofysiol. 2004;15:1258–62.CrossRefGoogle Scholar
  16. Silka MJ, Hardy BG, Menashe VD, Morris CD. A population-based prospective evaluation of risk of sudden death after operation for common congenital heart defects. J Am Coll Cardiol. 1998;32:45–51.Google Scholar
  17. The Antiarrhythmic Versus Implantable Defibrillator (AVID) Investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Eng J Med. 1997;337:1576–83.Google Scholar
  18. Wever EF, Hauer RN, Oomen J, et al. Unfavorable outcome in patients with primary electrical disease who survived an episode of ventricular fibrillation. Circulation. 1993;88:1021–9.PubMedCrossRefGoogle Scholar
  19. Yap SC, Roos-Hesselink JW, Hoendermis ES, et al. Outcome of implantable cardioverter defibrillators in adults with congenital heart disease: a multi-centre study. Eur Heart J. 2007;28:1854–61.PubMedCrossRefGoogle Scholar
  20. Zwanziger J, Hall J, Dick AW, et al. The cost effectiveness of implantable cardioverter-defibrillators: Results from the Multicenter Automatic Defribillator Implantation Trial (MADIT II). J Am Coll Cardiol. 2006;47:2310–18.PubMedCrossRefGoogle Scholar

Copyright information

© Bohn Stafleu van Loghum, Houten 2008

Authors and Affiliations

  • M. J. Schalij
    • 1
  • L. Van Erven
    • 1
  1. 1.Leids Universitair Medisch CentrumLeiden

Personalised recommendations